Pre-FDA01
Low Ejection Fraction
Detect reduced left-ventricular systolic function from a standard 12-lead ECG.
AI-ECG Algorithms
A growing portfolio of cardiac AI.
Each algorithm is validated through large clinical studies and must undergo regulatory review per region. FDA-clearance-pathway models targeting low and preserved ejection fraction, impaired cardiac relaxation, valvular disease, pulmonary embolism, right-ventricular function, and more.
A growing portfolio of cardiac AI.
Each algorithm is validated through large clinical studies and must undergo regulatory review per region.
Pre-FDA02
Preserved Ejection Fraction
Identify HFpEF indicators in patients whose EF reads as preserved on echo.
Pre-FDA03
Impaired Cardiac Relaxation
Diastolic dysfunction screening, the first algorithm in the MyoVista wavECG™ submission pathway.
Development04
Mitral Valve Regurgitation
Screen for valvular abnormalities historically requiring echocardiography.
Development05
Aortic Stenosis
Aortic valve disease detection in routine ECG recordings.
Development06
Pulmonary Embolism
Acute PE risk stratification at the point of care.
Development07
RV Size & Function
Quantitative right-ventricular size and function prediction (JAHA, 2024).
Development08
STEMI Detection
Elevated ST-segment / MI detection (HeartBEiT vision-transformer family).
Development09
Cardiomyopathy (PVC-related)
Predict cardiomyopathy risk in patients with premature ventricular complexes.
See it in context
Algorithms surface inside MyoVista Insights™.
Each AI-ECG model is wired into the same review workflow as the underlying ECG, so clinicians work in one place.